AstraZeneca Stock Leads The AI Healthcare Names Worth A Closer Look

Artificial intelligence in healthcare sits at the intersection of two powerful forces: the need to improve accuracy, access and affordability in medical care, and a global market that is watching inflation, energy prices and interest rates very closely. As central banks tread carefully and growth signals stay mixed, many investors are looking for long term themes grounded in real-world use cases rather than short term cycles. The Transformative AI Healthcare Stocks screener focuses on companies using AI to sharpen diagnostics, personalize treatments and streamline care. This article highlights 3 stocks from that screener for closer research.

IXICO (AIM:IXI)

Overview: IXICO is a London based healthcare data company that supports biopharma clinical trials by collecting, managing and analysing neuroimaging and other clinical data for conditions such as Alzheimer's, Huntington’s, Multiple Sclerosis and Parkinson’s disease. It acts as an imaging contract research partner, using its AI enabled IXICO platform to provide biomarkers, trial management and analytics that help drug developers assess whether new neurological therapies are working.

Operations: IXICO currently generates all of its £7.28 million in revenue from Medical Labs & Research services.

Market Cap: £18.53 million

IXICO provides targeted exposure to AI in neurology, where better imaging and data analysis can be critical for high stakes Alzheimer's and Parkinson's trials. The company is still loss making and forecasts indicate that earnings may decline over the next few years, so investors are exposed to profitability and dilution risk, especially after recent shareholder dilution and elevated borrowing. At the same time, revenue is expected to grow faster than the UK market and the stock trades on a lower P/S multiple than many Life Sciences peers. Some investors may interpret this as a sign that a significant amount of that risk is already reflected in the valuation. Recent clinical collaborations and contract wins show that the platform is being used in real world settings and gaining traction.

IXICO’s lower P/S and real world contracts suggest the market may be underpricing its AI neurology niche while focusing on current losses. See how the valuation compares with the risks in the DCF valuation analysis for IXICO

AstraZeneca (LSE:AZN)

Overview: AstraZeneca is a global biopharmaceutical company that develops, manufactures and sells prescription medicines across oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and rare diseases, with a broad portfolio that includes drugs such as Tagrisso, Imfinzi, Farxiga, Enhertu and Soliris.

Market Cap: £199.90 billion

Investors looking at AI powered healthcare may pay attention to AstraZeneca because it combines a broad late stage oncology and rare disease pipeline with the use of AI and digital tools to speed up clinical trials and sharpen patient selection. Earnings growth has been strong in recent years and return on equity is reported at 20.8%. At the same time, heavy R&D spending, high debt and growing exposure to price controls and biosimilars mean future cash flows depend on successful new launches and careful cost control. Recent regulatory approvals in areas such as breast cancer and other solid tumors illustrate how a productive pipeline can affect the company’s long term prospects.

AstraZeneca’s strong recent earnings and 20.8% return on equity suggest a far richer story than the headline figures. See how growth, debt, and future launches fit together in the analysis report for AstraZeneca

EMV Capital (AIM:EMVC)

Overview: EMV Capital is a London based venture capital company that backs early and growth stage businesses in areas such as digital health, diagnostics, therapeutics, robotics, semiconductors, AI and other healthcare technologies, with a focus on improving outcomes for people with chronic diseases. It typically invests through its own balance sheet in Europe, the UK and the United States and often seeks controlling stakes in its key subsidiaries.

Operations: EMV Capital currently generates about £2.87 million in revenue from Diagnostic Kits / Equipment, with most of that revenue coming from the United Kingdom.

Market Cap: £15.0 million

EMV Capital gives you exposure to a portfolio of AI, digital health and medical technology companies through a single small cap stock, which can be appealing if you want targeted access to early stage healthcare ideas without picking individual startups. Revenue of about £2.87 million and a very small reported loss for 2025 suggest the portfolio is at an early but commercially active stage, while the share price sits well below some fair value estimates and under the modelled future cash flow value of £1.10 per share. On the other hand, less than 1 year of cash runway, reliance on external debt and an auditor flagging going concern uncertainty in May 2026 underline the funding and balance sheet risk investors need to weigh carefully.

EMV Capital’s early stage revenue and small reported loss hint at a portfolio that could be misread at first glance. See what the full picture looks like in the analysis report for EMV Capital

The three stocks in this Transformative Artificial intelligence (AI) Healthcare Stocks idea are just a starting point, since the full screener has identified 3 more companies with equally compelling narratives in the Transformative Artificial intelligence (AI) Healthcare Stocks screener. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction AI healthcare opportunities.

Take Control of Your Investment Journey

If AstraZeneca or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

New breakouts and momentum shifts rarely stay under the radar for long. Spot fresh ideas while it matters and before prices get caught running away. Get in early.

• Target cash generative opportunities by scanning a curated 9 high quality undervalued stocks that filters for companies with strong cash flows and balance sheets before the crowd catches on.
• Ride long term income trends by reviewing a hand picked 6 dividend fortresses that focuses on higher yielding companies before demand pushes valuations higher.
• Track the next wave of automation by assessing a refined 34 robotics and automation stocks that highlights businesses building real world robotics and factory solutions while attention is still limited.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com